Human Metabolome Technologies, Inc. (TYO:6090)

Japan · Delayed Price · Currency is JPY

586.00

+9.00 (1.56%)

Jul 21, 2026, 3:30 PM JST

-23.30% (1Y)

Market Cap	3.26B -26.4%
Revenue (ttm)	1.30B -13.4%
Net Income	117.00M -63.3%
EPS	20.61 -61.8%
Shares Out	5.56M
PE Ratio	28.43
Forward PE	n/a
Dividend	18.00 (3.12%)
Ex-Dividend Date	Jun 29, 2026

Volume	5,300
Open	577.00
Previous Close	577.00
Day's Range	577.00 - 586.00
52-Week Range	570.00 - 797.00
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About TYO:6090

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, prec... [Read more]

Industry Medical - Diagnostics & Research

Sector Healthcare

Founded 2003

Employees 62

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 6090

Full Company Profile

Financial Performance

In fiscal year 2025, TYO:6090's revenue was 1.46 billion, an increase of 8.18% compared to the previous year's 1.35 billion. Earnings were 256.00 million, an increase of 5.35%.

Financial Statements